China Decode: What's at Stake Ahead of Trump and Xi's September Meeting, and China's Biotech Surge
Summary
China Decode examines the upcoming Trump-Xi summit, arguing China now holds the diplomatic upper hand through the SCO and rare earth dominance. The episode features Ruby Wong, author of "The China Cure," who details how China’s biotech sector is becoming a global superpower via rapid AI-driven drug discovery and massive out-licensing deals. The hosts also predict that China will soon surpass North America in clinical trial volume and that the STAR Market will eventually exceed the Hong Kong Stock Exchange in market cap.
Topics discussed
Sponsors: Juro AI and Indeed
Welcome to China Decode and intro
US-China trade truce and rare earth deadlines
Trump's weaker position and global relations
Shanghai Cooperation Organization and counter-West efforts
Summit outlook and AI cybersecurity cooperation
Rare earths leverage and summit expectations
Sponsors: NetSuite, Vanta, and Gusto
Introduction to China's biotech sector
Historical development of China's pharma industry
Rise in Chinese drug out-licensing deals
Guest background and book context
Factors attracting Western pharma to China
Patent cliff and opportunities for Chinese firms
US dependence on Chinese APIs and security
Cost advantages and AI in drug discovery
Conclusion of biotech interview
Sponsors: Lisa, LinkedIn, and NutriFol
Predictions: Clinical trials and Star Market
Listen ad-free on Castria